Study details
Enrolling now
Avapritinib Trial
M.D. Anderson Cancer Center
NCT IDNCT04771520ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
50
Study length
about 5.9 years
Ages
18+
Locations
1 site in TX
What this study is about
This trial is testing avapritinib, a medication, in people with certain genetic changes (CKIT or PDGFRA mutations) in their cancer cells. The goal is to see if avapritinib can help control the growth of these tumors.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Avapritinib
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
avapritinib
Drug routes
oral (Oral Tablet)
Endpoints
Primary: Overall response rate (ORR)
Secondary: Disease control rate (DCR), Duration of response (DoR), Incidence of adverse events
Body systems
Oncology